{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:30:56Z","timestamp":1791930656491,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1124\/molpharm.120.000202","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T11:25:23Z","timestamp":1627385123000},"page":"193-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein \u03b1 Variant with Balanced Safety and Effectiveness, from a Targeted Epitope Mammalian Cell-Displayed Antibody Library"],"prefix":"10.1016","volume":"100","author":[{"given":"Zhihong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naijing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuzhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaguo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingmu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beifen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.120.000202_bib1","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/molpharm.120.000202_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrclinonc.2017.149","article-title":"Immunotherapy: cancer vaccines on the move","volume":"15","author":"Banchereau","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1124\/molpharm.120.000202_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nri1859","article-title":"The SIRP family of receptors and immune regulation","volume":"6","author":"Barclay","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/molpharm.120.000202_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/bjc.2017.173","article-title":"CD47 overexpression is associated with decreased neutrophil apoptosis\/phagocytosis and poor prognosis in non-small-cell lung cancer patients","volume":"117","author":"Barrera","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1124\/molpharm.120.000202_bib5","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00018-016-2166-5","article-title":"Tumor-associated macrophages and anti-tumor therapies: complex links","volume":"73","author":"Belgiovine","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1124\/molpharm.120.000202_bib6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.abd9909","article-title":"De novo design of picomolar SARS-CoV-2 miniprotein inhibitors","volume":"370","author":"Cao","year":"2020","journal-title":"Science"},{"key":"10.1124\/molpharm.120.000202_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrc3171","article-title":"Programmed cell removal: a new obstacle in the road to developing cancer","volume":"12","author":"Chao","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/molpharm.120.000202_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1124\/molpharm.120.000202_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12777","article-title":"A novel human anti-AXL monoclonal antibody attenuates tumour cell migration","volume":"90","author":"Duan","year":"2019","journal-title":"Scand J Immunol"},{"key":"10.1124\/molpharm.120.000202_bib10","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1124\/molpharm.120.000202_bib11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1124\/molpharm.120.000202_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"10.1124\/molpharm.120.000202_bib13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.leukres.2015.04.007","article-title":"CD47 protein expression in acute myeloid leukemia: a tissue microarray-based analysis","volume":"39","author":"Galli","year":"2015","journal-title":"Leuk Res"},{"key":"10.1124\/molpharm.120.000202_bib14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.molcel.2008.05.026","article-title":"Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47","volume":"31","author":"Hatherley","year":"2008","journal-title":"Mol Cell"},{"key":"10.1124\/molpharm.120.000202_bib15","doi-asserted-by":"crossref","first-page":"14567","DOI":"10.1074\/jbc.M611511200","article-title":"The structure of the macrophage signal regulatory protein alpha (SIRPalpha) inhibitory receptor reveals a binding face reminiscent of that used by T cell receptors","volume":"282","author":"Hatherley","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.120.000202_bib16","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2020.06.008","article-title":"Macrocyclic peptide-mediated blockade of the CD47-SIRP\u03b1 interaction as a potential cancer immunotherapy","volume":"27","author":"Hazama","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1124\/molpharm.120.000202_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201832","article-title":"ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile","volume":"13","author":"Kauder","year":"2018","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.120.000202_bib18","doi-asserted-by":"crossref","first-page":"10133","DOI":"10.18632\/oncotarget.7100","article-title":"A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer","volume":"7","author":"Kaur","year":"2016","journal-title":"Oncotarget"},{"key":"10.1124\/molpharm.120.000202_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.biomaterials.2017.01.004","article-title":"Exosome-SIRP\u03b1, a CD47 blockade increases cancer cell phagocytosis","volume":"121","author":"Koh","year":"2017","journal-title":"Biomaterials"},{"key":"10.1124\/molpharm.120.000202_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"10.1124\/molpharm.120.000202_bib21","doi-asserted-by":"crossref","DOI":"10.1145\/2818302","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.120.000202_bib22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/cmi.2016.38","article-title":"Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library","volume":"15","author":"Luo","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"10.1124\/molpharm.120.000202_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12951-020-0571-2","article-title":"Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential","volume":"18","author":"Ma","year":"2020","journal-title":"J Nanobiotechnology"},{"key":"10.1124\/molpharm.120.000202_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1124\/molpharm.120.000202_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","article-title":"Resistance to PD1\/PDL1 checkpoint inhibition","volume":"52","author":"O\u2019Donnell","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/molpharm.120.000202_bib26","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRP\u03b1Fc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1124\/molpharm.120.000202_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1124\/molpharm.120.000202_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/07391102.2012.706073","article-title":"Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design","volume":"31","author":"Qiao","year":"2013","journal-title":"J Biomol Struct Dyn"},{"key":"10.1124\/molpharm.120.000202_bib29","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"10.1124\/molpharm.120.000202_bib30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1124\/molpharm.120.000202_bib31","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1124\/molpharm.120.000202_bib32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.clml.2013.05.001","article-title":"CD47 and osteopontin expression in diffuse large B-cell lymphoma with nodal and intravascular involvement","volume":"13","author":"Starr","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1124\/molpharm.120.000202_bib33","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3892\/ol.2017.6257","article-title":"Significance of CD47 expression in gastric cancer","volume":"14","author":"Sudo","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1124\/molpharm.120.000202_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","article-title":"SIRP\u03b1-CD47 immune checkpoint blockade in anticancer therapy","volume":"39","author":"Veillette","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1124\/molpharm.120.000202_bib35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/trf.15033","article-title":"Monoclonal anti-CD47 interference in red cell and platelet testing","volume":"59","author":"Velliquette","year":"2019","journal-title":"Transfusion"},{"key":"10.1124\/molpharm.120.000202_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1124\/molpharm.120.000202_bib37","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI81603","article-title":"CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer","volume":"126","author":"Weiskopf","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1124\/molpharm.120.000202_bib38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1238856","article-title":"Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies","volume":"341","author":"Weiskopf","year":"2013","journal-title":"Science"},{"key":"10.1124\/molpharm.120.000202_bib39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.canlet.2015.02.036","article-title":"Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma","volume":"360","author":"Xiao","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1124\/molpharm.120.000202_bib40","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/0008-5472.CAN-09-1474","article-title":"An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis","volume":"70","author":"Zabuawala","year":"2010","journal-title":"Cancer Res"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24011350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24011350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.120.000202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:45:59Z","timestamp":1739954759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24011350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0026895X24011350"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.120.000202","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein \u03b1 Variant with Balanced Safety and Effectiveness, from a Targeted Epitope Mammalian Cell-Displayed Antibody Library","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.120.000202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}